Shanghai Junshi Biosciences (SHJBF) Stock Price, News & Analysis

Company Overview

Shanghai Junshi Biosciences Co., Ltd. is a Shanghai-based biopharmaceutical company dedicated to the research, development and commercialization of monoclonal antibody therapeutics. Since its founding in 2012 as a spin-off from the Shanghai Institute of Pharmaceutical Industry, Junshi has focused on leveraging cutting-edge antibody engineering platforms to develop innovative treatments for oncology, autoimmune conditions, infectious diseases and metabolic disorders. The company’s lead product, toripalimab (Tuoyi), was among the first anti-PD-1 antibodies approved by Chinese regulatory authorities for the treatment of advanced melanoma and nasopharyngeal carcinoma, demonstrating Junshi’s capability to translate research into commercially available immuno-oncology therapies.

Junshi’s pipeline encompasses a diversified portfolio of antibody-based candidates targeting immune checkpoints, cytokines and other disease-associated proteins. Beyond toripalimab, the company is advancing multiple clinical-stage assets such as anti-CD38 and anti-IL-6 antibodies, as well as antibody–drug conjugates designed to deliver cytotoxic agents directly to tumor cells. To support these programs, Junshi has established state-of-the-art research and manufacturing facilities in Shanghai, with supplementary laboratories in Beijing and collaborative research centers in North America and Europe, ensuring global compliance and quality standards throughout drug development.

In addition to its own R&D efforts, Shanghai Junshi Biosciences has entered into strategic collaborations with leading international pharmaceutical partners. These alliances leverage complementary expertise in clinical development, regulatory affairs and global marketing to accelerate the availability of new therapies across multiple indications. Junshi primarily serves patients throughout the People’s Republic of China while advancing regulatory filings for its key assets in the United States, Europe and other international markets, reflecting its ambition to emerge as a globally recognized innovator in the biopharmaceutical industry.

Key Stats

• Today's Range: C$4.23 to C$4.23
• 50-Day Range: C$1.97 to C$4.23
• 52-Week Range: C$3.93 to C$4.23
• Volume: N/A
• Average Volume: 100 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SHJBF Stock Analysis - Frequently Asked Questions

How have SHJBF shares performed this year?

Shanghai Junshi Biosciences' stock was trading at C$1.24 at the start of the year. Since then, SHJBF shares have increased by 241.0% and is now trading at C$4.23.

How do I buy shares of Shanghai Junshi Biosciences?

Shares of SHJBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SHJBF
• CIK: N/A
• Web: www.junshipharma.com
• Phone: 86 21 6105 8800
• Fax: N/A
• Employees: 2,568
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A